The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
As monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)SELECT
Endocrine Tumours
Thyroid cancer - differentiated
MKI targeting VEGFR1, VEGFR2 and VEGFR3
SELECT
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Sorafenib
-
Placebo
Treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodineDECISION
Endocrine Tumours
Thyroid cancer - differentiated
MKI targeting VEGFR, PDGFR and Raf family kinases
DECISION
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Vandetanib
-
Placebo
Treatment of aggressive and symptomatic MTC in patients with unresectable locally acvanced or metastatic disease in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decisionZETA
Endocrine Tumours
Thyroid Cancer - medullary
MKI targeting RET, VEGFR2 and EGFR
ZETA
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Cabazitaxel
Prednisone or prednisolone
Abiraterone or enzalutamide (alternative to previously used)
In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimenCARD
Genitourinary Cancers
Prostate cancer
-
CARD
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Ramucirumab
-
Placebo
As monotherapy for the treatment of adult patients with advanced or unresectable HCC who have serum AFP of ≥ 400 ng/ml and who have been previously treated with sorafenibREACH-2
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
REACH-2
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
1
Dacomitinib
-
Gefitinib
As monotherapy for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR activating mutations.ARCHER 1050
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
ARCHER 1050
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Lorlatinib
-
Single arm
As monotherapy is indicated for the treatment of adult patients with ALK+ advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK TKI therapy; or crizotinib and at least one other ALK TKIB7461001
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
B7461001
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Larotrectinib
-
Single arm (Phase I/II)
Adult and paediatric patients with solid tumours that display an NTRK gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment optionsSCOUT and NAVIGATE
Refractory NTRK fusion-positive cancers
-
NTRK gene fusion
SCOUT and NAVIGATE
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Olaparib
-
Placebo
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapySOLO-1
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
BRCA mutation
SOLO-1
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Olaparib
-
Placebo
Maintenance therapy in relapsed high-grade cancer of the ovaries, fallopian tubes and peritoneum with BRCA mutations after previous treatment and in whom platinum-based chemotherapy has reduced or cleared the cancerSOLO-2
Gynaecological Malignancies
Ovarian, fallopian tubes and peritoneum cancer
BRCA mutation
SOLO-2
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Trifluridine/Tipiracil (TAS-102)
-
Placebo
Metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, in patients who have been previously treated with ≥2 prior systemic treatment regimens for advanced diseaseTAGS
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
-
TAGS
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Pembrolizumab
Axitinib
Sunitinib
First-line treatment of advanced RCC in adultsKEYNOTE-426
Genitourinary Cancers
Renal cell cancer
-
KEYNOTE-426
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Avelumab
Axitinib
Sunitinib
First-line treatment of adult patients with advanced RCCJAVELIN Renal 101
Genitourinary Cancers
Renal cell cancer
-
JAVELIN Renal 101
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Lanreotide
-
Placebo
Grade 1 and a subset of grade 2 (Ki67 index up to 10%) GEP-NETs of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic diseaseCLARINET
Endocrine Tumours
Neuroendocrine Tumour - Entero-pancreatic
Ki67 index up t o 10%
CLARINET
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Everolimus
Best supportive care
Placebo
Unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive diseaseRADIANT 3
Endocrine Tumours
Neuroendocrine Tumour - Pancreatic
-
RADIANT 3
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Octreotide
-
Placebo
Treatment of patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excludedPROMID
Endocrine Tumours
Neuroendocrine Tumour - Midgut
-
PROMID
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Sunitinib
-
Placebo
Treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours with disease progression in adults
Endocrine Tumours
Neuroendocrine Tumour - Pancreatic
-
-
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
177Lu-DOTATATE
Best supportive care + octreotide
Octreotide
Unresectable or metastatic, progressive, well-differentiated (Grade 1 and Grade 2), somatostatin receptor positive-GEP-NETs in adultsNETTER-1
Endocrine Tumours
Neuroendocrine Tumour - Midgut
-
NETTER-1
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Brigatinib
-
Single arm
Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALK positive advanced NSCLC previously treated with crizotinibALTA
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ALTA
4
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
4
Pembrolizumab
Carboplatin and either paclitaxel or nab-paclitaxel
Carboplatin and either paclitaxel or nab-paclitaxel
First-line metastatic squamous non-small cell lung cancer KEYNOTE-407
Thoracic Malignancies
Non-small-cell Lung Cancer
-
KEYNOTE-407
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Atezolizumab
Bevacizumab, paclitaxel and carboplatin
Bevacizumab, paclitaxel and carboplatin
In combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC)IMpower150
Thoracic Malignancies
Non-small-cell Lung Cancer
-
IMpower150
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Atezolizumab
Bevacizumab, paclitaxel and carboplatin
Bevacizumab, paclitaxel and carboplatin
In patients with EGFR mutant or ALK-positive NSCLC, atezolizumab, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapiesIMpower150
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+ or ALK-positive
IMpower150
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Atezolizumab
Carboplatin plus nab-paclitaxel
Carboplatin plus nab-paclitaxel
In combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLCIMpower130
Thoracic Malignancies
Non-small-cell Lung Cancer
-
IMpower130
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Ribociclib
Endocrine therapy
Placebo + endocrine therapy
Treatment of women with HR+, HER2 negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist.MONALEESA-7
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-7
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Abemaciclib
Aromatase inhibitor
Placebo + aromatase inhibitor
EMA: First-line treatment of hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer. FDA: Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancerMONARCH 3
Breast Cancer
Breast Cancer
HR+ HER2-
MONARCH 3
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Abemaciclib
Fulvestrant
Fulvestrant + placebo
Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONARCH 2
Breast Cancer
Breast Cancer
HR+ HER2-
MONARCH 2
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Ribociclib
Fulvestrant
Placebo + fulvestrant
Treatment of women with hormone receptor-positive, HER2-negative locally advanced or MBC as initial endocrine-based therapy, or in women who have received prior ET MONALEESA-3
Breast Cancer
Breast Cancer
HR+ HER2-
MONALEESA-3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Fulvestrant
-
Anastrozole
Treatment of estrogen receptor positive (ER+), locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapyFALCON
Breast Cancer
Breast Cancer
ER+
FALCON
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Alpelisib
Fulvestrant
Placebo + fulvestrant
Treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, locally advanced or MBC with a PIK3CA mutation after disease progression following ET as monotherapy SOLAR-1
Breast Cancer
Breast Cancer
PIK3CA-mutated HR+ HER2-
SOLAR-1
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Trastuzumab deruxtecan
-
Single arm study (Phase II)
HER2-positive breast cancer that is metastatic (has spread to other parts of the body) or cannot be removed by surgery. HER2-positive means that the cancer cells produce a protein called HER2 in large quantities on their surface, which makes the tumour cells grow more quickly. Used on its own in patients who have received one or more HER2-targeted treatmentsDESTINY-Breast01
Breast Cancer
Breast Cancer
HER2+
DESTINY-Breast01
2
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
2
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.